# Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis

> **NCT04794946** · NA · UNKNOWN · sponsor: **Institute of Liver and Biliary Sciences, India** · enrollment: 2200 (estimated)

## Conditions studied

- Liver Cirrhosis

## Interventions

- **BIOLOGICAL:** Covishield

## Key facts

- **NCT ID:** NCT04794946
- **Lead sponsor:** Institute of Liver and Biliary Sciences, India
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-03-19
- **Primary completion:** 2022-03-19
- **Final completion:** 2022-03-19
- **Target enrollment:** 2200 (ESTIMATED)
- **Last updated:** 2021-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04794946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04794946, "Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04794946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*